fda warning compounded semaglutide october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our US FDA sends 25 letters

BPC-157 is non-hormonal and bodyweight-independent , so typical dosages apply to both men and women

Edta, Potassium 47

Obesity is a complex condition so many factors contribute to its occurrence (and reoccurrence) over time, and these factors are not the same for all people, says Gudzune

23-25 The FDA-approved indication for weight management use of GLP-1 RAs is a BMI of 30 or higher, or a BMI of 27 or higher with at least 1 other cardiometabolic comorbidity such as type 2 diabetes or hyperlipidemia

Many patients reach meaningful weight loss at the 0.5 to 0.75 mg dose range during the three-month window, while others require the full 1.0 mg maintenance dose for optimal results